News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NeurogesX, Inc. (NGSX) NGX-1998 Phase 2 Study Data to be Presented at World Congress on Pain



7/17/2012 9:34:02 AM

SAN MATEO, Calif., July 16, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (OTCQB:NGSX) (OTCBB:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies, today announced that it plans to present data from its Phase 2 study on NGX-1998 at the 14th World Congress on Pain, to be held August 27-31, 2012, at the Milano Convention Centre in Milan, Italy. NGX-1998 is the Company's next generation liquid formulation of prescription strength capsaicin.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES